Command Palette

Search for a command to run...

Clinical Trials · NCT05051579

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

CompletedPhase 2Orforglipron (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
272
Start date
Sep 2021
Locations
35 sites, 4 countries
Primary endpoint
Percent Change From Baseline in Body Weight in LY3502970 and Placebo
View Orforglipron compound reference